Breast Cancer Update: A CME Audio Series and Activity

STATEMENT OF NEED/TARGET AUDIENCE

Breast cancer is one of the most rapidly evolving fields in medical oncology. Published results from a plethora of ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well-informed of these advances. To bridge the gap between research and patient care, Breast Cancer Update uses one-on-one discussions with leading oncology investigators. By providing access to the latest research developments and expert perspectives, this CME program assists medical oncologists in the formulation of up-to-date clinical management strategies.

GLOBAL LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Critically evaluate the clinical implications of emerging clinical trial data in breast cancer treatment.
• Describe and implement an algorithm for HER2 testing and treatment of HER2-positive breast cancer patients in your practice.
• Develop and explain a management strategy for treatment of ER-positive breast cancer in the adjuvant, neoadjuvant and metastatic settings.
• Develop and explain a management strategy for treatment of ER-negative breast cancer in the adjuvant, neoadjuvant and metastatic settings.
• Counsel ER-positive, postmenopausal patients about the risks and benefits of aromatase inhibitors in the adjuvant setting.
• Evaluate the emerging data on dose-dense chemotherapy and explain its relevance to patients.

SPECIFIC LEARNING OBJECTIVES FOR ISSUE 6

Upon completion of this activity, participants should be able to:

• Utilize the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines when selecting chemotherapy, hormonal therapy and biologic therapy for patients with breast cancer.
• Consider the implications of the Phase II trial of gefitinib in women with metastatic breast cancer for the treatment of patients with metastases progressing on previous chemotherapy regimens.
• Determine which clinical trials are available to patients who are at high risk for developing breast cancer in order to counsel select patients who are interested in breast cancer chemoprevention.
• Discuss the use of sequential single-agent versus combination chemotherapy for the treatment of metastatic breast cancer.

ACCREDITATION STATEMENT

NL Communications Inc is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

NL Communications Inc designates this educational activity for a maximum of 3.25 category 1 credits towards the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent on the activity.

Home · Search